4540:TSETsumura & Co. Analysis
Data as of 2026-06-19 - not real-time
NT$61.20
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Tbi Motion is trading at TWD 61.2, below its 20‑day (≈67) and 50‑day (≈64) SMAs but still above the 200‑day average, indicating a price that is modestly supported by longer‑term momentum. The RSI sits at 43.5, suggesting neutral to slightly bearish sentiment, while the MACD histogram is negative and the signal line is bearish, reinforcing short‑term downside pressure. Volatility is elevated at roughly 74% over the past month, yet the computed beta of 0.61 points to lower systematic risk, and the market mood is marked by an “Extreme Greed” fear‑greed index of 91.34, which may be inflating price expectations. Revenue surged 67% year‑over‑year, but profitability remains weak with a gross margin of only 10.9% and operating margin at –5.4%, leading to negative EPS and a forward P/E of –130. The balance sheet is strained, featuring a debt‑to‑equity ratio of 95.5 and total debt far exceeding cash reserves, while free cash flow is deeply negative. Despite these challenges, analysts have issued a “buy” rating with a modest upside target of TWD 67.6, implying a potential 10.5% upside from current levels. Overall, the stock shows strong top‑line growth but is hampered by earnings deficits, high leverage, and an over‑extended valuation relative to its fundamentals.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price hovering just above the identified support level of TWD 58.2
- bearish MACD and decreasing volume indicating limited upside
- neutral RSI suggesting no strong momentum
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- robust 67% revenue growth offering upside potential
- persistent negative margins and heavy debt burden
- valuation still above fair value given earnings deficits
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- strong top‑line growth trajectory in the precision motion market
- potential for operational turnaround and debt restructuring
- analyst consensus buy rating with a modest upside target
Key Metrics & Analysis
Financial Health
Revenue Growth67.10%
Profit Margin-0.65%
P/E Ratio-130.2
ROE-0.56%
ROA-1.97%
Debt/Equity95.49
P/B Ratio2.1
Op. Cash FlowNT$-811564992
Free Cash FlowNT$-635083392
Industry P/E31.4
Technical Analysis
TrendBullish
RSI43.5
SupportNT$58.20
ResistanceNT$81.90
MA 20NT$67.05
MA 50NT$63.92
MA 200NT$47.15
MACDBearish
VolumeDecreasing
Fear & Greed Index91.34
Valuation
Target PriceNT$67.60
Upside/Downside10.46%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.61
Volatility74.17%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.